Next Article in Journal
How to Obtain a Mega-Intestine with Normal Morphology: In Silico Modelling of Postnatal Intestinal Growth in a Cd97-Transgenic Mouse
Next Article in Special Issue
Gene Therapy in Hemophilia: Recent Advances
Previous Article in Journal
Inflammation and Anti-Inflammatory Targets after Aneurysmal Subarachnoid Hemorrhage
Previous Article in Special Issue
Purine Nucleotides Metabolism and Signaling in Huntington’s Disease: Search for a Target for Novel Therapies
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 22
Issue 14
10.3390/ijms22147352
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy

by
Francesca Marini
1,2 and
Maria Luisa Brandi
2,*
1
Department of Experimental and Clinical Biomedical Sciences, University of Florence, Viale Pieraccini 6, 50139 Florence, Italy
2
F.I.R.M.O., Italian Foundation for the Research on Bone Diseases, Via Reginaldo Giuliani 195/A, 50141 Florence, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(14), 7352; https://doi.org/10.3390/ijms22147352
Submission received: 16 June 2021 / Revised: 7 July 2021 / Accepted: 7 July 2021 / Published: 8 July 2021
(This article belongs to the Special Issue Rare Monogenic Diseases: Molecular Pathophysiology and Novel Therapies)
Browse Figure
Versions Notes

Abstract

:
Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant inherited multiple cancer syndrome of neuroendocrine tissues. Tumors are caused by an inherited germinal heterozygote inactivating mutation of the MEN1 tumor suppressor gene, followed by a somatic loss of heterozygosity (LOH) of the MEN1 gene in target neuroendocrine cells, mainly at parathyroids, pancreas islets, and anterior pituitary. Over 1500 different germline and somatic mutations of the MEN1 gene have been identified, but the syndrome is completely missing a direct genotype-phenotype correlation, thus supporting the hypothesis that exogenous and endogenous factors, other than MEN1 specific mutation, are involved in MEN1 tumorigenesis and definition of individual clinical phenotype. Epigenetic factors, such as microRNAs (miRNAs), are strongly suspected to have a role in MEN1 tumor initiation and development. Recently, a direct autoregulatory network between miR-24, MEN1 mRNA, and menin was demonstrated in parathyroids and endocrine pancreas, showing a miR-24-induced silencing of menin expression that could have a key role in initiation of tumors in MEN1-target neuroendocrine cells. Here, we review the current knowledge on the post-transcriptional regulation of MEN1 and menin expression by miR-24, and its possible direct role in MEN1 syndrome, describing the possibility and the potential approaches to target and silence this miRNA, to permit the correct expression of the wild type menin, and thereby prevent the development of cancers in the target tissues.

1. Introduction

Multiple endocrine neoplasia type 1 (MEN1) is a rare autosomal dominant inherited cancer syndrome that causes the development of multiple endocrine and non-endocrine tumors in a single patient [1,2]. The main affected organs are parathyroid glands, anterior pituitary, and the neuroendocrine cells of the gastro-entero-pancreatic tract. Morbidity and mortality of the disease are related to hormone over-secretion by endocrine functioning tumors, leading to the development of specific syndromes, and/or to the malignant progression of silent tumors, such as non-functioning neuroendocrine neoplasms of the pancreas and the thymus.
Medical therapies of MEN1 aim to control hormone over-secretion and tumor growth. Surgery is the main treatment employed for parathyroid adenomas and gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) [3]. No therapeutic intervention is definitively resolutive; given the genetic nature of the syndrome and the asynchronous development of tumors, MEN1 patients have a high prevalence of post-operative tumor recurrences, both in the parathyroids and the gastro-entero-pancreatic tract [4]. Therefore, there is a strong need for novel therapies acting at the molecular level and able to prevent tumors in the target neuroendocrine cells. The comprehension of molecular mechanisms underlying MEN1 tumorigenesis is fundamental to identify possible targets for the design of novel therapies [2].
In 1997, the causative gene, MEN1, was identified at the 11q13 locus [5]. The MEN1 gene is a classic tumor suppressor gene: The first inactivating heterozygote mutation is inherited by the affected parent (first hit), while the second copy of the gene is somatically lost in target neuroendocrine cells (second hit), mainly by a large deletion at the 11q13 locus or, more rarely, by a second intragenic loss-of-function mutation (loss of heterozygosity; LOH) [6,7]. The MEN1 gene encodes menin, a nuclear protein which exerts a wide spectrum of key activities, such as control of cell cycle and apoptosis, regulation of gene transcription and chromatin structure, and DNA repair [8]. Loss of both wild type MEN1 copies, resulting in loss of menin functions, appears to be the trigger of tumor initiation in MEN1 target neuroendocrine cells. However, the absence of a complete genotype-phenotype correlation and the different tumor manifestations between carriers of the same MEN1 mutation (even homozygote twins) suggest that other factors concur to cause MEN1 individual tumorigenesis. Epigenetic factors are the main suspected co-actors in driving tumor development and progression in MEN1 target neuroendocrine cells [9]. Alterations in the normal epigenetic regulation of gene transcription (histone modification and/or DNA methylation), following the loss of wild type menin activity, have been demonstrated to play an important role in the progression of MEN1 pancreatic neuroendocrine tumors [10].
Among epigenetic regulators of gene expression, microRNAs (miRNAs) have recently been shown to be involved in the development of various human malignancies, either acting directly as oncogenes (oncomiRs) or inhibiting the expression of tumor suppressor genes [11]. These molecules are non-coding small RNAs that normally negatively regulate gene expression by directly binding the 3′UTR of their target mRNAs [12,13,14]. Through the activity of tissue- and cell-specific miRNAs, the organism regulates the expression of numerous genes, in a spatial and temporal way, granting the correct functionality of various and important biological processes [15,16]. Alterations of expression and/or activity of one or more miRNAs can lead to disease development, including cancer. A role of miRNAs has been demonstrated in the initiation of various human malignancies [17,18,19] and in development of metastases [20,21].
In the last two decades, tissue-specific altered activity and/or expression of miRNAs have been suggested as possible modulators of MEN1 tumorigenesis [22,23,24,25], acting synergically with the MEN1 mutation, indicating the miR-24 as a possible effector of tumor development.
Here, we review results from recent studies that demonstrate the existence of an autoregulatory network between miR-24, MEN1 mRNA, and menin, suggesting possible roles of this miRNA in MEN1 tumorigenesis, and we discuss the possibility to silence this molecule in MEN1 mutation carriers to prevent/reduce cancer development and/or progression.

2. The Autoregulatory Network between miR-24, MEN1, and Menin: A Possible Effector of MEN1 Tumorigenesis

miR-24 is encoded by two separated chromosomal locations: one gene cluster located on chromosome 9q22, which includes miR-23b, miR-27b, and miR-24-1; and a second gene cluster located on chromosome 19p13, which includes miR-23a, miR-27a, and miR-24-2 [26]. The two miR-24 mature isoforms are identical in nucleotide sequencing, regardless of the different chromosomal origin.
Using Miranda, Target Scan, and Pictar Vert prediction software, Luzi et al. predicted the 599-605 nt position of the 832 nt-3′UTR of MEN1 mRNA as a direct target of miR-24-1 [27]. The seed site of miR-24-1, which binds to MEN1 mRNA 3′UTR, is highly conserved in humans, rats, mice, chickens, and dogs. The direct targeting of MEN1 mRNA was demonstrated in vitro for the first time in 2012 by Luzi et al. [27] in the BON1 cells, a human cell line derived from a lymph node metastasis of a serotonin-secreting pancreatic neuroendocrine tumor [28], via luciferase report assays. Authors showed that the induced over-expression of miR-24-1, through the transfection of pri-miR-24, inhibited the expression of menin protein, while the silencing of the endogenous miR-24-1, through the transfection of a specific 2′-O-methyl-RNA miR-24-1 antisense, resulted in an increased expression of menin, suggesting the existence of a direct negative feedback loop between miR-24-1 and menin, which could have a role in MEN1 tumorigenesis.
Later, in 2016, the same research group [29] demonstrated in BON1 cells that, in addition to the negative feedback loop between miR-24-1, MEN1 mRNA, and menin, there was also a feedforward loop in which menin protein directly binds to the pri-miR-24-1 (the primary mRNA precursor of miR-24-1), promoting the DROSHA-mediated processing to pre-miR-24-1 and, thus, the biogenesis of mature miR-24-1. Moreover, the specific siRNA-induced silencing of menin expression in BON1 cells resulted in a complete suppression of pri-miR-24-1 expression, indicating an essential and direct role of menin in miR-24-1 synthesis, that is exerted by acting both at the transcriptional and at the post-transcriptional modification levels of the miR-24-1 synthesis. Conversely, when an overexpression of menin is induced in BON1 cells, this leads to an increased expression of mature miR-24-1. Authors showed that menin specifically binds to pri-miR-24-1, but not to pri-miR-24-2, and that the silencing of menin expression had no effect on the pri-miR-24-2 expression and the processing to pre-miR-24-2.
The proposed autoregulatory network between miR-24-1, MEN1 mRNA, and menin is shown in Figure 1.
The regulatory network between miR-24, MEN1, and menin was demonstrated also in other species, than humans, in vitro and in vivo [30,31,32]. Interestingly, Gao et al. [30] demonstrated, both by Target Scan algorithm-based prediction and by an in vitro study in neonatal rat cardiac myocytes, that miR-24 targets the CDNK1B mRNA, blocking translation of the encoded p27kip1 protein, a negative regulator of cell cycle, resulting in a decreased G0/G1 arrest and in cell hypertrophy. Inactivating mutations of the CDNK1B tumor suppressor gene are responsible for the development of multiple endocrine neoplasia type 4 (MEN4), a clinical phenocopy of MEN1 [33]. Therefore, miR-24 could also have a role in MEN4 tumorigenesis.

2.1. miR-24, MEN1 mRNA, and Menin in Parathyroid Glands

Luzi et al. first demonstrated a direct regulation of menin expression by miR-24-1 in parathyroid tissues from MEN1 patients [27], suggesting an epigenetic oncogenic role of this miRNA in the tissue-specific tumorigenesis of these glands in MEN1 mutation carriers. The analysis of miR-24-1 expression profiles in parathyroid adenomas from MEN1 mutation carriers, in sporadic non-MEN1 tumor counterparts and in healthy parathyroid tissue, showed an inverse correlation in the expression profiles of miR-24-1 and menin, indicating a direct role of miR-24-1 in the post-transcriptional negative regulation of menin expression itself. This inverse correlation was present only when the wild type copy of the MEN1 gene was still retained in the tumoral tissue, while in MEN1 adenomas presenting LOH at the 11q13 locus, menin resulted to be unexpressed and miR-24-1 was expressed at a very low level. The chromatin immunoprecipitation (ChIP) analysis, with an anti-menin antibody, in parathyroid tissues from MEN1 patients, showed the occupancy of miR-24-1 promoter region by menin, only in parathyroid adenomas conserving one wild type copy of the MEN1 gene, but not in tumors presenting MEN1 LOH, and it confirmed menin as a positive regulator of miR-24-1 expression, as previously demonstrated in BON1 cells [27].
Results from this study suggested that, in MEN1-associated parathyroid tumors, after the first inherited germinal “hit”, the somatic onset and progression of neoplasia could be under the control of a negative feedback loop between menin protein and miR-24-1. Authors hypothesized that this regulatory network could mimic and substitute the second somatic “hit” of tumor suppressor inactivation in tissues in which MEN1 LOH has not yet occurred, probably representing an intermediate step before the irreversible genetic MEN1 LOH. The pathway leading to MEN1 tumor development and progression could be explained by the proposed negative feedback loop between menin and miR-24-1 acting as a “homeostatic regulatory network” that needs to be “broken” to induce the somatic LOH “hit” and, consequently, the progression to neoplasia. This mechanism could explain the proliferative changes in the neuroendocrine cells (hyperplasia) that precede neoplasia, and this could also be hypothesized for pancreatic, duodenal, and other MEN1-associated tumors.
Some years later, the same Research Group [34] failed to find both miR-24-1 and miR-24-2 as differentially expressed between MEN1 parathyroid adenomas with somatic MEN1 LOH at 11q13 and MEN1 parathyroid adenomas still retaining one wild type copy of the MEN1 gene when they performed a microarray expression profiling covering about 1890 human miRNAs and using a p-value < 0.05 and a log2 fold change > 1.5 as parameters of statistical significance.
Grolmusz et al. [23] compared the expression of six potential MEN1-targeting miRNAs, including miR-24, in MEN1-associated parathyroid adenomas/hyperplasia with a germinal MEN1 mutation (16), in sporadic counterparts bearing a somatic MEN1 mutation (10) and in sporadic parathyroid lesions wild type for the MEN1 gene (40). Expression levels of miR-24 and miR-28 were found to be significantly higher in sporadic primary hyperparathyroidism (PHPT) tissues with respect to MEN1-associated adenomas/hyperplasia, both when all the sporadic samples were considered and when considering the two sporadic PHPT subgroups of samples positive for nuclear menin staining or of samples negative for nuclear menin staining separately. No significant expression differences were found between the MEN1 mutated vs. the MEN1 wild type nuclear menin-negative sporadic lesions. All these data seemed to identify the higher expression of miR-24 and miR-28 as two universal signatures of sporadic non-syndromic parathyroid hyperplasia/adenoma, independent of their somatic genetic profile.

2.2. miR-24, MEN1 mRNA, and Menin in the Endocrine Pancreas

In the duodenum and the pancreas, the MEN1 gene-associated heterozygote germline mutation causes hyperplasia of insulin- gastrin-, somatostatin-, and glucagon-secreting cells, resulting in a subsequent multifocal development of tumors. The great majority of tumors analyzed showed allelic deletion/inactivation of the second copy of the MEN1 gene, whereas the precursor lesions retained their MEN1 heterozygosity [35]. Pancreatic endocrine tumors develop from beta islets, through a stage of islet hyperplasia in which the wild-type MEN1 allele is still retained. LOH at MEN1 locus has never been found in these enlarged islets and, therefore, these lesions are considered to be a precursor stage of the tumors. It is possible that these pancreatic lesions present the same mechanism evidenced in MEN1 parathyroid glands: The proposed negative feedback loop between miR-24, MEN1 mRNA and menin.
In 2014, Vijayaraghavan et al. [36] confirmed the presence of a feedback loop between miR-24 and menin, similar to that identified in parathyroids, in cell lines of endocrine pancreas (the MIN6 cells derived from a mouse insulinoma and the Blox5 cells, an immortalized cell line produced from a purified population of human pancreas beta cells by infection with retroviral vectors). Authors confirmed the direct interaction of miR-24 with the 3′UTR of MEN1 mRNA. Cell transfection with pre-miR-24 increased miR-24 levels and resulted in a reduction of MEN1 and menin expression, of 35% and 23% in MIN6 cells and 61% and 38% in Blox5 cells, respectively. Conversely, cell transfection with an anti-miR-24 antisense decreased endogenous miR-24 levels, in association with an increased MEN1 expression in MIN6 cells but not in Blox5 cells, and with no significant difference of menin expression in both MIN6 and Blox5 cells. At the same time, an induced overexpression of menin increased the expression of mature miR-24 both in MIN6 (2.5-fold increase) and Blox5 (0.6-fold increase) cells, confirming that miR-24 and menin reciprocally regulate their expression. The negative effect of menin depletion on miR-24 expression was also confirmed in vivo in a conditional knockout mouse model with a selective deletion of the MEN1 gene in pancreas beta cells, in which reductions of about 60% and 90% of miR-24 levels were found in heterozygote and homozygote knocked-out animals, respectively [36].
In the same study, since in the pancreas menin is known to regulate gene expression in a transcription complex with mixed-lineage leukemia (MLL) factor, the Authors [36] hypothesized the possibility that the miR-24-1- and miR-24-2-encoding genes could be targets of menin/MLL complex. The ChiP analysis in MIN6 and Blox5 cells showed that both menin and MLL proteins were present in the region upstream of miR-24, both on chromosomes 9 and 19, confirming the importance of the menin/MLL complex in miR-24 expression in pancreas islets.
Finally, since menin is known to negatively regulate cell proliferation by transcriptionally regulating expression of two main cell cycle inhibitors, p27kip1 and p18ink4c, the Authors also investigated the impact of miR-24 expression on these two proteins. Cell transfection with pre-miR-24 induced a 42% reduction of both p27 mRNA and protein in MIN6 cells, and of 57% p27 mRNA, but not protein, in Blox5 cells, and a reduction of 48% of p18 mRNA, but not protein, in Blox5 cells. No effect on both expressions of p18 mRNA and protein was found in MIN6 cells. Inhibition of miR-24 expression by transfection with an anti-miR-24 antisense did not significantly affect p18 mRNA nor protein expression in MIN6 and Blox5 cells [36]. The fact that an increased expression of miR-24 reduced the expression of p27 and p18 mRNAs suggested this miRNA as negatively regulating the expression of these two cell cycle inhibitors in an indirect manner, via the suppression of menin translation. In this way, the increased expression of miR-24, and the subsequent silencing of menin, lead to a significantly increased cell proliferation in Blox5 cells, but not in insulinoma-derived MIN6 cells, in which cell growth is already at such a high level as to not be further influenced by menin, p27, and p18 inhibition. Considering this, it can be assumed that an increase in miR-24 expression could be responsible for enhanced proliferation of beta-cells and hyperplasia of pancreas islets in the first stage of MEN1 tumorigenesis.
Molecular effects of miR-24 in parathyroid glands and endocrine pancreas and possible roles in MEN1 tumorigenesis, reported in the currently available studies, are summarized in Table 1.

2.3. miR-24, MEN1 mRNA, and Menin in Non-MEN1 Tumors

Menin has been found to exert its tumor suppression activity by blocking cell hyperplasia in tissues other than those commonly affected by MEN1 syndrome, such as prostate, breast, lung, liver, and stomach [37].
Using the A549 cells (a continuous cell line derived from a human adenocarcinoma of the alveolar basal epithelium of the lungs) and the NCI-H446 cells (a cell line derived from a human small-cell lung tumor), Pan et al. [38] also confirmed the interaction of miR-24 with the 3′UTR of MEN1 mRNA and the miR-24-mediated significant silencing of menin expression in lung cancer.
The induced overexpression of miR-24 in A549 cells inhibited menin expression and upregulated SMAD3 and cyclin D1, stimulating cell proliferation and, at the same time, increased expression of Bcl-2 and inhibited expression of Bax, resulting in the inhibition of cell apoptosis [38]. Conversely, the induced silencing of endogenous miR-24 increased menin expression and downregulated SMAD3 and cyclin D1, inhibiting cell growth, and, at the same time, inhibited Bcl-2 expression and promoted Bax expression, allowing cell apoptosis [38]. In addition, the induced overexpression of miR-24, in both A549 and NCI-H446 cell lines, upregulated SMAD3 and MMP2 and significantly enhanced cell migration and invasion, while downregulation of miR-24 decreased the expression of both SMAD3 and MMP2, preventing cell migration and invasion. Taken together, these data indicate miR-24 as an oncogenic effector in lung cancer cells, acting as promoter of both cell proliferation and metastatic spread.
In the same study, the analysis of surgical specimens from human lung cancer showed a higher expression of miR-24, and a mirrored lower expression of menin, in tumors with respect to the adjacent healthy tissues. miR-24 expression inversely correlated with tumor size and patient overall survival, while patients with a higher menin expression showed a longer survival rate [38].
Bronchopulmonary carcinoids of the neuroendocrine cells of the bronchial epithelium arise in approximately 5–8% of MEN1 patients [39]. Despite the different cytological origin with respect to lung cancers studied by Pan et al. [38], an involvement of the miR-24-MEN1 mRNA-menin network in the tumorigenesis of these carcinoids in MEN1 syndrome cannot be excluded.
Although menin has been found to regulate cell proliferation in hepatocellular carcinoma [40], the exact role of menin in liver carcinogenesis has not yet been widely studied, and the liver is not a site of primary tumor development in MEN1 syndrome, but only metastases from pancreas and duodenal MEN1-related neuroendocrine tumors. Ehrlich et al. [37] studied the miR-24-MEN1 mRNA-menin network in six human cell lines of intrahepatic and extrahepatic cholangiocarcinoma (CCA), a biliary epithelial adenocarcinoma whose cells adopt a neuroendocrine-like phenotype during their proliferation. Both MEN1 mRNA and menin expression resulted significantly decreased in all six CCA-derived cell lines compared to a human immortalized, non-malignant, cholangiocyte cell line (H69). A further-induced silencing of menin in tumoral cells increased cell growth, while the induced menin overexpression reduced the cell proliferation rate together with a decreased cell migration and invasion.
All the six tumoral cell lines showed a basal overexpression of miR-24 with respect to the H69 control, as well as human CCA tumor samples compared with their matched healthy tissues. The induced knock-down of miR-24 was associated with an increase of menin expression, a decreased expression of pro-angiogenic and pro-proliferative factors, and a reduction of cell proliferation and migration.

3. Targeting miR-24: A Potential Therapeutic Tool for MEN1 Tumorigenesis

The miR-24-driven post-transcriptional inhibition of menin synthesis, in parathyroid cells and pancreas beta islets, could represent an intermediate epigenetic step guiding the MEN1 tumorigenesis. menin has been demonstrated to have a role in the maintenance of genome stability and DNA repair, protecting cells from DNA damage [41,42]. At the same time, the epigenetic silencing of wild type menin by miR-24 promotes cell proliferation and exposes cells to DNA damage, which could result in deletion at the 11q13 locus or mutation of the second copy of the MEN1 gene, favoring the somatic MEN1 LOH, which represents a common hallmark of MEN1 cancers in parathyroids and endocrine pancreas.
In light of this, it is conceivable that targeting and silencing the expression of miR-24 at this intermediate, still reversible, step, before the occurrence of the genetic, irreversible, MEN1 LOH, could restore expression and activity of wild type menin and block neoplastic initiation and progression, representing a promising innovative tool for preventing tumor development and progression in MEN1 patients [43].
Silencing of a miRNA that has an oncogenic activity (oncomiR), such as miR-24 in MEN1, can be obtained by miRNA inhibition target therapies, that include antisense anti-miRNAs (synthetic anti-miRNA oligonucleotides (AMOs), modified synthetic AMOs, locked nucleic acids (LNA)-based AMOs, and antagomirs), small molecules miRNA inhibitors, miRNA sponges, and miRNA masks. These anti-oncomiR tools, and their characteristics, are depicted in Table 2.
Among the above mentioned oncomiR inhibitor target therapies, transfection of target cells with RNA antagomirs [45] appears to be a promising tool for miR-24 silencing in MEN1. Synthetic RNA antagomirs for the in vivo silencing of endogenous miRNAs were first created in 2005; intravenous injection of these molecules in mice has been shown to considerably reduce the expression of target miRNA, with a silencing effect lasting up to three weeks after systemic administration [50]. Currently, this technology appears to be a promising tool for the treatment of different types of human cancer and other diseases [51,52,53], also thanks to the fact that antagomirs do not activate any immune response.
RNA antagomirs consist in single strand RNAs, complementary to the target miRNAs to be inhibited, presenting specific chemical modifications (introduction of a 2′-O-methyl residue to nucleotides and substitution of an oxygen atom with an atom of sulfur within the phosphodiester bonds; phosphorothioate bond), to reduce RNA degradation by endogenous ribonucleases and conjugated with a cholesterol tail at the 3′-end to enhance permeation of cell membrane and intracellular distribution [54,55].
To further improve the efficacy of this exogenous delivery system, it is possible to conjugate, through electrostatic interactions, the anionic RNA antagomir with polymeric cations possessing extremely low toxicity and immunogenicity (i.e., polyethylenimine; PEI), able to grant high efficiency of cell transfection, increase the bond to the target miRNA, and, at the same time, protect the transfected molecule from intracellular lysosomal degradation [56,57].
In addition, it is possible to conjugate the RNA antagomir-PEI complex with paramagnetic nanoparticles (PMNP), which give the RNA antagomir-PEI-PMNP complex the potential to be specifically conveyed in vivo, after a systemic intravenous injection, to target cells and tissues, in which we want to silence the target miRNA, through the application of external magnetic fields [58,59,60].
Luzi et al. [29] tested a 2′-O-methyl-modified antisense RNA complementary to hsa-miR-24-1 in the BON1 cells, measuring the effect of transfection of this molecule on both miR-24-1 and menin expression. Transfection of this antisense RNA caused a specific inhibition of activity of the endogenous miR-24-1, with a subsequent over-expression of menin, with respect to BON1 cells transfected with a scrambled sequence RNA as control.
These preliminary and promising results, obtained in basic research, show the ability of the anti-miR-24-1 antagomir to target and inhibit the human endogenous miR-24-1 and restore the normal expression of wild type menin, and prompt the possibility to develop and design RNA antagomir-PEI-PMNP complexes against hsa-miR-24, for systemic administration to MEN1 patients and prevention of tumor development.
A first attempt to evaluate in vivo the therapeutic effect of the miR-24 silencing on tumor growth was performed by Ehrlich et al. [37] in an athymic nude mouse model in which the CCA were induced by injection of Mz-ChA-1, a human cell line of extrahepatic CCA. After the development of tumors, treated mice were injected, three times a week, with a commercial miR-24 hairpin inhibitor, while the control group received an injection of a scramble (inactive) hairpin inhibitor. Ten weeks after the first injection, treated animals showed a significant reduction in tumor size compared to untreated controls, in association with a decreased nuclear Ki-67 staining in tumor specimens. Quantitative expression analysis, performed on tumor samples from treated and control mice, showed a decreased expression of both pro-angiogenic and pro-proliferative factors in treated animals. Results from this study clearly show that targeting miR-24 represents a promising therapeutic tool for reducing biliary tumor growth and suggest the possibility of using the same approach for other tumors, the tumorigenesis of which involves the oncomiR miR-24 and its inhibitory action on the MEN1 tumor suppressor gene.

4. Future Research Needed in the Field of MEN1 Syndrome and miRNAs

In addition to miR-24, other miRNAs showed to be possibly involved in the MEN1 tumorigenesis or to be deregulated in the sporadic tumor counterparts of the neuroendocrine tissues commonly affected in MEN1 syndrome [25], and they should be further investigated by functional studies, as was done for miR-24, to assess their importance in MEN1-related tumor development and progression.
In this paragraph we briefly summarized the most promising miRNAs, that could be involved in the tumorigenesis of the three MEN1 main affected endocrine tissues.
Luzi et al. [34] profiled the expression of 1890 human miRNAs between MEN1 parathyroid adenomas with somatic MEN1 LOH or still retain one wild type copy of the MEN1 gene, and with respect to non-MEN1 sporadic parathyroid adenomas. After both the microarray analysis and the quantitative RT-PCR validation, three miRNAs were identified as differentially expressed between the two groups of MEN1 tumors. Authors analyzed, by ComiR tool, the putative gene targets of these three differentially expressed miRNAs, with a focus on genes known to be involved in parathyroid tumorigenesis. miR-4258 resulted remarkably downregulated in MEN1 parathyroid adenomas with MEN1 LOH, with respect to those without MEN1 LOH. miR-4258 was predicted to target the gene encoding the cyclin D1 (CCND1), a positive regulator of cell cycle and cell growth, suggesting that, in the absence of wild type menin, cells lose the miR-4258-driven negative control of CCND1 expression, presumably leading to an uncontrolled cell growth. Conversely, miR-664 resulted to be upregulated in MEN1 non-LOH adenomas and down-regulated in MEN1 LOH adenomas, both with respect to non-MEN1 controls. miR-664 was predicted to target the CDC73 tumor suppressor gene, whose germinal inactivating mutations are responsible for the hyperparathyroidism-jaw tumor syndrome [61] and somatic mutations have been associated with the development of sporadic parathyroid carcinoma [62], and the CDKN2C tumor suppressor gene encoding the p18ink4c, an inhibitor of the cyclin kinases CDK4 and CDK6, that negatively controls the cell cycle G1 progression. When a copy of the wild type MEN1 gene is conserved, it can be speculated that the over-expression of miR-664 leads to silence these tumor suppressor genes, resulting in promoting cell growth and favoring tumor initiation. miR-1301 resulted upregulated in MEN1 LOH parathyroid adenomas, both with respect to the MEN1 non-LOH parathyroid adenomas and the non-MEN1 controls. miR-1301 was predicted to target the CDKN1B tumor suppressor gene, whose inactivating mutations are responsible for MEN4 syndrome, the RET oncogene, whose activating mutations are responsible for the multiple endocrine neoplasia type 2 (MEN2) syndrome, the AP2S1 gene, whose loss-of-function mutations have been associated with familial hypocalciuric hypercalcemia type 3, the CCND2 gene encoding cyclin D2 a positive regulator of cell cycle, and the CTNNB1 gene encoding the catenin beta 1, involved in the regulation of cell adhesion. These data on expression and in silico analyses suggested these three miRNAs as potentially involved in MEN1 parathyroid tumorigenesis. The interaction of these three miRNAs with MEN1 and menin protein should be functionally investigated, to better understand the exact role of these epigenetic regulators in the development and progression of parathyroid tumors, including their possible role in parathyroid carcinoma, which is extremely rare in MEN1 patients and appeared not to be directly correlated with the MEN1 mutation. In addition, expression and functional role of these three miRNAs should be also studied in other MEN1 target tissues, to verify if their possible oncogenic role is tissue-specific only to parathyroid glands or, as for miR-24, they act in other MEN1-associated malignancies. Indeed, the CDKN2C gene, which could be a target of miR-664, has been demonstrated to be frequently lost in pituitary adenomas [63].
Regarding the endocrine pancreas, Lu et al. [64] showed that the miR-17, whose expression is induced by glucose and hyperglycemia, directly downregulated menin expression, through targeting the 3′UTR of the MEN1 mRNA, promoting proliferation of the pancreas beta cells. On the other hand, MEN1 is not only a direct target of miRNAs, but it has been showed also to regulate the biogenesis of some miRNAs that are involved in insulin-signaling and insulin-induced proliferation of pancreas beta cells. Through its direct physical interaction with the arsenite-resistance protein 2 (ARS2), a component of the nuclear RNA cap-binding complex that stabilizes pri-miRNA, menin facilitates the processing of pri-let-7a and pri-miR-155 to pre-let-7a and pre-miR-155 [65]. IRS2, a protein involved in the insulin-signaling pathway, is a target of mature let-7a, and resulted to be over-expressed when MEN1 expression is lost. miR-155, whose biogenesis is positively regulated by menin, had been previously showed to be s among the top downregulated miRNAs in pancreatic neuroendocrine tumors [66], and its downregulation could have a role also in MEN1 tumorigenesis of the endocrine pancreas.
Two miRNAs, miR-15a and miR-16-1, that had been previously shown as having a significantly reduced expression in human sporadic pituitary adenomas [67], were reported to be downregulated also in MEN1 pituitary tumors from Men1+/− mice, with respect to the healthy pituitary tissue [68]. The expression of these two miRNAs inversely correlated with the expression of cyclin D1 [68], suggesting their possible tumor suppressor gene-like role in pituitary tumorigenesis. The Men1 knockdown in the AtT20 mouse pituitary cell lines resulted in a significantly decreased expression of miR-15a [68], suggesting that the decrease of miR-15a expression in the pituitary cells of MEN1 patients may be a direct result of menin expression lost, that may concur to MEN1 pituitary tumorigenesis. Study on human specimens and functional studies are needed to confirm these preliminary findings.

5. Conclusions

  • The absence of a genotype-phenotype correlation in MEN1 syndrome suggested a possible role of epigenetic factors in the development of the individual clinical phenotype in any single patient, even in presence of the same MEN1 mutation.
  • miRNAs have shown increasing evidence of a direct role in human malignancies, both for sporadic and hereditary cancers. Several miRNAs resulted to be deregulated in the sporadic tumor counterparts of the neuroendocrine tissues commonly affected in MEN1 syndrome. A role of specific mi-RNA deregulation also in MEN1 tumorigenesis can be suspected.
  • miR-24 has been demonstrated to negatively regulate menin expression in the parathyroids and the endocrine pancreas in MEN1 syndrome, and in other non-MEN1 sporadic tumors, suggesting it as initiator of menin loss-derived tumorigenesis.
  • Targeting/silencing miR-24, during the hyperplastic phase of parathyroid and endocrine pancreas tumorigenesis and before the occurrence of the somatic MEN1 LOH, could by a promising tissue-specific RNA-based anti-cancer therapy, aimed to restore the correct expression of menin in pre-cancerous cells.

Author Contributions

F.M. and M.L.B. contributed equally to write the manuscript. Both authors have read and agreed to the published version of the manuscript.

Funding

This review received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Thakker, R.V.; Newey, P.J.; Walls, G.V.; Bilezikian, J.; Dralle, H.; Ebeling, P.R.; Melmed, S.; Sakurai, A.; Tonelli, F.; Brandi, M.L. Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 2012, 97, 2990–3011. [Google Scholar] [CrossRef]
  2. Brandi, M.L.; Agarwal, S.K.; Perrier, N.D.; Lines, K.E.; Valk, G.D.; Thakker, R.V. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr. Rev. 2021, 42, 133–170. [Google Scholar] [CrossRef]
  3. Geslot, A.; Vialon, M.; Caron, P.; Grunenwald, S.; Vezzosi, D. New therapies for patients with multiple endocrine neoplasia type 1. Ann. Endocrinol. 2021, 82, 112–120. [Google Scholar] [CrossRef]
  4. Al-Salameh, A.; Cadiot, G.; Calender, A.; Goudet, P.; Chanson, P. Clinical aspects of multiple endocrine neoplasia type 1. Nat. Rev. Endocrinol. 2021, 17, 207–224. [Google Scholar] [CrossRef]
  5. Chandrasekharappa, S.C.; Guru, S.C.; Manickam, P.; Olufemi, S.E.; Collins, F.S.; Emmert-Buck, M.R.; Debelenko, L.V.; Zhuang, Z.; Lubensky, I.A.; Liotta, L.A.; et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276, 404–407. [Google Scholar] [CrossRef] [PubMed]
  6. Pannett, A.A.; Thakker, R.V. Somatic mutations in MEN type 1 tumors, consistent with the Knudson “two-hit” hypothesis. J. Clin. Endocrinol. Metab. 2001, 86, 4371–4374. [Google Scholar] [CrossRef]
  7. Valdes, N.; Alvarez, V.; Diaz-Cadorniga, F.; Aller, J.; Villazon, F.; Garcia, I.; Herrero, A.; Coto, E. Multiple endocrine neoplasia type 1 (MEN1): LOH studies in an affected family and in sporadic cases. Anticancer Res. 1998, 18, 2685–2689. [Google Scholar] [PubMed]
  8. Dreijerink, K.M.A.; Timmers, H.T.M.; Brown, M. Twenty years of menin: Emerging opportunities for restoration of transcriptional regulation in MEN1. Endocr. Relat. Cancer 2017, 24, T135–T145. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Feng, Z.; Ma, J.; Hua, X. Epigenetic regulation by the menin pathway. Endocr. Relat. Cancer 2017, 24, T147–T159. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Marini, F.; Giusti, F.; Tonelli, F.; Brandi, M.L. Pancreatic Neuroendocrine Neoplasms in Multiple Endocrine Neoplasia Type 1. Int. J. Mol. Sci. 2021, 22, 4041. [Google Scholar] [CrossRef]
  11. Svoronos, A.A.; Engelman, D.M.; Slack, F.J. OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer. Cancer Res. 2016, 76, 3666–3670. [Google Scholar] [CrossRef] [Green Version]
  12. O’Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol. 2018, 9, 402. [Google Scholar] [CrossRef] [Green Version]
  13. Bartel, D.P. MicroRNAs: Target recognition and regulatory functions. Cell 2009, 136, 215–233. [Google Scholar] [CrossRef] [Green Version]
  14. Shukla, G.C.; Singh, J.; Barik, S. MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. Mol. Cell Pharmacol. 2011, 3, 83–92. [Google Scholar]
  15. Tüfekci, K.U.; Meuwissen, R.L.J.; Genç, S. The role of microRNAs in biological processes. Methods Mol. Biol. 2014, 1107, 15–31. [Google Scholar] [CrossRef] [PubMed]
  16. Vidigal, J.A.; Ventura, A. The biological functions of miRNAs: Lessons from in vivo studies. Trends Cell Biol. 2015, 25, 137–147. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  17. Peng, Y.; Croce, C.M. The role of MicroRNAs in human cancer. Signal. Transduct. Target. Ther. 2016, 1, 15004. [Google Scholar] [CrossRef] [Green Version]
  18. Lin, Y.-C.; Tso-Hsiao Chen, T.-H.; Huang, Y.-M.; Wei, P.-L.; Lin, J.-C. Involvement of microRNA in Solid Cancer: Role and Regulatory Mechanisms. Biomedicines 2021, 9, 343. [Google Scholar] [CrossRef] [PubMed]
  19. Tan, W.; Liu, B.; Qu, S.; Liang, G.; Luo, W.; Gong, C. MicroRNAs and cancer: Key paradigms in molecular therapy. Oncol. Lett. 2018, 15, 2735–2742. [Google Scholar] [CrossRef] [Green Version]
  20. Bouyssou, J.M.; Manier, S.; Huynh, D.; Issa, S.; Roccaro, A.M.; Ghobrial, I.M. Regulation of microRNAs in cancer metastasis. Biochim. Biophys. Acta 2014, 1845, 255–265. [Google Scholar] [CrossRef] [Green Version]
  21. Jafri, M.A.; Al-Qahtani, M.H.; Shay, J.W. Role of miRNAs in human cancer metastasis: Implications for therapeutic intervention. Semin. Cancer Biol. 2017, 44, 117–131. [Google Scholar] [CrossRef] [PubMed]
  22. Nagy, Z.; Szabó, P.M.; Grolmusz, V.K.; Perge, P.; Igaz, I.; Patócs, A.; Igaz, P. MEN1 and microRNAs: The link between sporadic pituitary, parathyroid and adrenocortical tumors? Med. Hypotheses 2017, 99, 40–44. [Google Scholar] [CrossRef] [PubMed]
  23. Grolmusz, V.K.; Borka, K.; Kövesdi, A.; Németh, K.; Balogh, K.; Dékány, C.; Kiss, A.; Szentpéteri, A.; Sármán, B.; Somogyi, A.; et al. MEN1 mutations and potentially MEN1-targeting miRNAs are responsible for menin deficiency in sporadic and MEN1 syndrome-associated primary hyperparathyroidism. Virchows Arch. 2017, 471, 401–411. [Google Scholar] [CrossRef]
  24. Luzi, E.; Pandolfini, L.; Ciuffi, S.; Marini, F.; Cremisi, F.; Nesi, G.; Brandi, M.L. MicroRNAs regulatory networks governing the epigenetic landscape of MEN1 gastro-entero-pancreatic neuroendocrine tumor: A case report. Clin. Transl. Med. 2021, 11, e351. [Google Scholar] [CrossRef]
  25. Donati, S.; Ciuffi, S.; Marini, F.; Palmini, G.; Miglietta, F.; Aurilia, C.; Brandi, M.L. Multiple Endocrine Neoplasia Type 1: The Potential Role of microRNAs in the Management of the Syndrome. Int. J. Mol. Sci. 2020, 21, 7592. [Google Scholar] [CrossRef]
  26. Lal, A.; Navarro, F.; Maher, C.A.; Maliszewski, L.E.; Yan, N.; O’Day, E.; Chowdhury, D.; Dykxhoorn, D.M.; Tsai, P.; Hofmann, O.; et al. miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to “seedless” 3’UTR microRNA recognition elements. Mol. Cell 2009, 35, 610–625. [Google Scholar] [CrossRef] [Green Version]
  27. Luzi, E.; Marini, F.; Giusti, F.; Galli, G.; Cavalli, L.; Brandi, M.L. The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the “Knudson’s second hit”. PLoS ONE 2012, 7, e39767. [Google Scholar] [CrossRef] [PubMed]
  28. Evers, B.M.; Ishizuka, J.; Townsend, C.M., Jr.; Thompson, J.C. The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Ann. N. Y. Acad. Sci. 1994, 733, 393–406. [Google Scholar] [CrossRef] [PubMed]
  29. Luzi, E.; Marini, F.; Ciuffi, S.; Galli, G.; Brandi, M.L. An autoregulatory network between menin and pri-miR-24-1 is required for the processing of its specific modulator miR-24-1 in BON1 cells. Mol. Biosyst. 2016, 12, 1922–1928. [Google Scholar] [CrossRef]
  30. Gao, J.; Zhu, M.; Liu, R.-F.; Zhang, J.-S.; Xu, M. Cardiac Hypertrophy is Positively Regulated by MicroRNA-24 in Rats. Chin. Med. J. 2018, 131, 1333–1341. [Google Scholar] [CrossRef]
  31. Hall, C.; Ehrlich, L.; Meng, F.; Invernizzi, P.; Bernuzzi, F.; Lairmore, T.C.; Alpini, G.; Glaser, S. Inhibition of microRNA-24 increases liver fibrosis by enhanced menin expression in Mdr2(−/−) mice. J. Surg. Res. 2017, 217, 160–169. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Qiaoqiao, C.; Li, H.; Liu, X.; Yan, Z.; Zhao, M.; Xu, Z.; Wang, Z.; Shi, K. MiR-24-3p regulates cell proliferation and milk protein synthesis of mammary epithelial cells through menin in dairy cows. J. Cell Physiol. 2019, 234, 1522–1533. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Alrezk, R.; Hannah-Shmouni, F.; Stratakis, C.A. MEN4 and CDKN1B mutations: The latest of the MEN syndromes. Endocr. Relat. Cancer. 2017, 24, T195–T208. [Google Scholar] [CrossRef] [Green Version]
  34. Luzi, E.; Ciuffi, S.; Marini, F.; Mavilia, C.; Galli, G.; Brandi, M.L. Analysis of differentially expressed microRNAs in MEN1 parathyroid adenomas. Am. J. Transl Res. 2017, 9, 1743–1753. [Google Scholar] [PubMed]
  35. Falchetti, A.; Marin, F.; Luzi, E.; Giusti, F.; Cavalli, L.; Cavalli, T.; Brandi, M.L. Multiple endocrine neoplasia type 1 (MEN1): Not only inherited endocrine tumors. Genet. Med. 2009, 11, 825–835. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Vijayaraghavan, J.; Maggi, E.C.; Crabtree, J.S. miR-24 regulates menin in the endocrine pancreas. Am. J. Physiol Endocrinol. Metab. 2014, 307, E84–E92. [Google Scholar] [CrossRef]
  37. Ehrlich, L.; Hall, C.; Venter, J.; Dostal, D.; Bernuzzi, F.; Invernizzi, P.; Meng, F.; Trzeciakowski, J.P.; Zhou, T.; Standeford, H.; et al. miR-24 Inhibition Increases Menin Expression and Decreases Cholangiocarcinoma Proliferation. Am. J. Pathol. 2017, 187, 570–580. [Google Scholar] [CrossRef] [Green Version]
  38. Pan, Y.; Wang, H.; Ma, D.; Ji, Z.; Luo, L.; Cao, F.; Huang, F.; Liu, Y.; Dong, Y.; Chen, Y. miR-24 may be a negative regulator of menin in lung cancer. Oncol. Rep. 2018, 39, 2342–2350. [Google Scholar] [CrossRef] [Green Version]
  39. Montero, C.; Sanjuán, P.; del Mar Fernández, M.; Vidal, I.; Verea, H.; Cordido, F. Bronchial carcinoid and type 1 multiple endocrine neoplasia syndrome. A case report. Arch. Bronconeumol. 2010, 46, 559–561. (In Spanish) [Google Scholar] [CrossRef]
  40. Gang, D.; Hongwei, H.; Hedai, L.; Ming, Z.; Qian, H.; Zhijun, L. The tumor suppressor protein menin inhibits NF-κB-mediated transactivation through recruitment of Sirt1 in hepatocellular carcinoma. Mol. Biol. Rep. 2013, 40, 2461–2466. [Google Scholar] [CrossRef]
  41. Gallo, A.; Agnese, S.; Esposito, I.; Galgani, M.; Avvedimento, V.E. Menin stimulates homology-directed DNA repair. FEBS Lett. 2010, 584, 4531–4536. [Google Scholar] [CrossRef] [Green Version]
  42. Jin, S.; Mao, H.; Schnepp, R.W.; Sykes, S.M.; Silva, A.C.; D’Andrea, A.D.; Hua, X. Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Res. 2003, 63, 4204–4210. [Google Scholar]
  43. Gambari, R.; Brognara, E.; Spandidos, D.A.; Fabbri, E. Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review). Int. J. Oncol. 2016, 49, 5–32. [Google Scholar] [CrossRef] [Green Version]
  44. Dias, N.; Stein, C.A. Antisense oligonucleotides: Basic concepts and mechanisms. Mol. Cancer Ther. 2002, 1, 347–355. [Google Scholar]
  45. Mattes, J.; Yang, M.; Foster, P.S. Regulation of microRNA by antagomirs: A new class of pharmacological antagonists for the specific regulation of gene function? Am. J. Respir. Cell Mol. Biol. 2007, 36, 8–12. [Google Scholar] [CrossRef]
  46. Vester, B.; Wengel, J. LNA (locked nucleic acid): High-affinity targeting of complementary RNA and DNA. Biochemistry 2004, 43, 13233–13241. [Google Scholar] [CrossRef] [PubMed]
  47. Wen, D.; Danquah, M.; Chaudhary, A.K.; Mahato, R.I. Small molecules targeting microRNA for cancer therapy: Promises and obstacles. J. Control. Release 2015, 219, 237–247. [Google Scholar] [CrossRef] [Green Version]
  48. Ebert, M.S.; Sharp, P.A. MicroRNA sponges: Progress and possibilities. RNA 2010, 16, 2043–2050. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Wang, Z. The principles of MiRNA-masking antisense oligonucleotides technology. Methods Mol. Biol. 2011, 676, 43–49. [Google Scholar] [CrossRef] [PubMed]
  50. Krützfeldt, J.; Rajewsky, N.; Braich, R.; Rajeev, K.G.; Tuschl, T.; Manoharan, M.; Stoffel, M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005, 438, 685–689. [Google Scholar] [CrossRef]
  51. Preethi, K.A.; Lakshmanan, G.; Sekar, D. Antagomir technology in the treatment of different types of cancer. Epigenomics 2021, 13, 481–484. [Google Scholar] [CrossRef]
  52. Murdaca, G.; Tonacci, A.; Negrini, S.; Greco, M.; Borro, M.; Puppo, F.; Gangemi, S. Effects of AntagomiRs on Different Lung Diseases in Human, Cellular, and Animal Models. Int. J. Mol. Sci. 2019, 20, 3938. [Google Scholar] [CrossRef] [Green Version]
  53. Innao, V.; Allegra, A.; Pulvirenti, N.; Allegra, A.G.; Musolino, C. Therapeutic potential of antagomiRs in haematological and oncological neoplasms. Eur. J. Cancer Care 2020, 29, e13208. [Google Scholar] [CrossRef]
  54. Krutzfeldt, J.; Kuwajima, S.; Braich, R.; Rajeev, K.G.; Pena, J.; Tuschl, T.; Manoharan, M.; Stoffel, M. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 2007, 35, 2885–2892. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Lennox, K.A.; Behlke, M.A. Chemical modification and design of anti-miRNA oli-gonucleotides. Gene Ther. 2011, 18, 1111–1120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Fu, Y.; Chen, J.; Huang, Z. Recent progress in microRNA-based delivery systems for the treatment of human disease. ExRNA 2019, 1, 24. [Google Scholar] [CrossRef] [Green Version]
  57. Dasgupta, I.; Anushila Chatterjee, A. Recent Advances in miRNA Delivery Systems. Methods Protoc. 2021, 4, 10. [Google Scholar] [CrossRef] [PubMed]
  58. Muthana, M.; Scott, S.D.; Farrow, N.; Morrow, F.; Murdoch, C.; Grubb, S.; Brown, N.; Dobson, J.; Lewis, C.E. A novel magnetic approach to enhance the efficacy of cell-based gene therapies. Gene Ther. 2008, 15, 902–910. [Google Scholar] [CrossRef]
  59. Revia, R.A.; Stephen, Z.R.; Zhang, M. Theranostic Nanoparticles for RNA-Based Cancer Treatment. Acc. Chem Res. 2019, 52, 1496–1506. [Google Scholar] [CrossRef]
  60. Hofmann, A.; Wenzel, D.; Becher, U.M.; Freitag, D.F.; Klein, A.M.; Eberbeck, D.; Schulte, M.; Zimmermann, K.; Bergemann, C.; Gleich, B.; et al. Combined targeting of lentiviral vectors and positioning of transduced cells by magnetic nanoparticles. Proc. Natl. Acad. Sci. USA 2009, 106, 44–49. [Google Scholar] [CrossRef] [Green Version]
  61. Carpten, J.D.; Robbins, C.M.; Villablanca, A.; Forsberg, L.; Presciuttini, S.; Bailey-Wilson, J.; Simonds, W.F.; Gillanders, E.M.; Kennedy, A.M.; Chen, J.D.; et al. HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 2002, 32, 676–680. [Google Scholar] [CrossRef]
  62. Shattuck, T.M.; Välimäki, S.; Obara, T.; Gaz, R.D.; Clark, O.H.; Shoback, D.; Wierman, M.E.; Tojo, K.; Robbins, C.M.; Carpten, J.D.; et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. 2003, 349, 1722–1729. [Google Scholar] [CrossRef] [PubMed]
  63. Kirsch, M.; Mörz, M.; Pinzer, T.; Schackert, H.K.; Schackert, G. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas. Genes Chromosomes Cancer 2009, 48, 143–154. [Google Scholar] [CrossRef] [PubMed]
  64. Lu, Y.; Fei, X.-Q.; Yang, S.-F.; Xu, B.-K.; Li, Y.-Y. Glucose-induced microRNA-17 promotes pancreatic beta cell proliferation through down-regulation of Menin. Eur. Rev. Med. Pharmacol. Sci. 2015, 19, 624–629. [Google Scholar] [PubMed]
  65. Gurung, B.; Katona, B.W.; Hua, X. Menin-mediated regulation of miRNA biogenesis uncovers the IRS2 pathway as a target for regulating pancreatic beta cells. Oncoscience 2014, 1, 562–566. [Google Scholar] [CrossRef]
  66. Roldo, C.; Missiaglia, E.; Hagan, J.P.; Falconi, M.; Capelli, P.; Bersani, S.; Calin, G.A.; Volinia, S.; Liu, C.G.; Scarpa, A.; et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24, 4677–4684. [Google Scholar] [CrossRef]
  67. Bottoni, A.; Piccin, D.; Tagliati, F.; Luchin, A.; Zatelli, M.C.; degli Uberti, E.C. miR-15a and miR-16-1 down-regulation in pituitary adenomas. J. Cell Physiol. 2005, 204, 280–285. [Google Scholar] [CrossRef]
  68. Lines, K.E.; Newey, P.J.; Yates, C.J.; Stevenson, M.; Dyar, R.; Walls, G.V.; Bowl, M.R.; Thakker, R.V. miR-15a/miR-16-1 expression inversely correlates with cyclin D1 levels in Men1 pituitary NETs. J. Endocrinol. 2018, 240, 41–50. [Google Scholar] [CrossRef] [Green Version]
Ijms 22 07352 g001 550
Figure 1. Schematic representation of the autoregulatory network between miR-24-1, MEN1 mRNA, and menin. (A) menin binds the upstream region of the miR-24-1-encoding gene cluster on chromosome 9, promoting the transcription of pri-miR-24-1; (B) menin directly interacts with the primary transcript of miR-24-1, pri-miR-24-1, facilitating the DROSHA-mediated processing to pre-miR-24-1, in a positive feedforward loop in which menin promotes the maturation of the repressor of its own expression, miR-24-1. Mature miR-24-1, together with the RISC complex, binds the 3′ UTR of MEN1 mRNA blocking translation of menin.
Figure 1. Schematic representation of the autoregulatory network between miR-24-1, MEN1 mRNA, and menin. (A) menin binds the upstream region of the miR-24-1-encoding gene cluster on chromosome 9, promoting the transcription of pri-miR-24-1; (B) menin directly interacts with the primary transcript of miR-24-1, pri-miR-24-1, facilitating the DROSHA-mediated processing to pre-miR-24-1, in a positive feedforward loop in which menin promotes the maturation of the repressor of its own expression, miR-24-1. Mature miR-24-1, together with the RISC complex, binds the 3′ UTR of MEN1 mRNA blocking translation of menin.
Ijms 22 07352 g001
Table
Table 1. Molecular effects of miR-24 parathyroid glands and endocrine pancreas, and possible roles in MEN1 tumorigenesis.
Table 1. Molecular effects of miR-24 parathyroid glands and endocrine pancreas, and possible roles in MEN1 tumorigenesis.
miR-24 TargetEffectPossible Role in MEN1 TumorigenesisReference
Parathyroid glands
MEN1No effect on MEN1 mRNA expression. Loss of menin protein expression.Uncontrolled cell proliferation[27]
Endocrine pancreas
MEN1Reduction of both MEN1 mRNA and menin expression.Uncontrolled cell proliferation[36]
CDKN1BReduction of expression of both CDKN1B mRNA and of p27kip1 protein in a mouse insulinoma cell line (MIN6).Enhanced proliferation of beta-cells and hyperplasia of pancreas islets[36]
CDKN1BReduction of expression of CDKN1B mRNA in an immortalized human pancreas beta cell line (Blox5). No data on expression of p27kip1 protein.Enhanced proliferation of beta-cells and hyperplasia of pancreas islets[36]
CDKN2CNo effect on expression of both CDKN2C mRNA and of p18Ink4c protein in a mouse insulinoma cell line (MIN6).Non applicable[36]
CDKN2CReduction of expression of CDKN2C mRNA in an immortalized human pancreas beta cell line (Blox5). No data on expression of p18Ink4c protein.Enhanced proliferation of beta-cells and hyperplasia of pancreas islets[36]
Table
Table 2. miRNA inhibition target therapies for oncomiRs.
Table 2. miRNA inhibition target therapies for oncomiRs.
Therapeutic ToolDescriptionMechanism of Action on the Target oncomiRReference
Anti-miRNA oligonucleotides (AMOs)Synthetic single-stranded RNA molecules complementary to the target miRNACompetitive inhibition of the target mature miRNA by base pair[44]
Modified AMOsAMOs with a chemical modification of the 2′-OH into 2′-O′methyl- or 2′-O′methoxyethyl- groups, to increase intracellular stabilityCompetitive inhibition of the target mature miRNA by base pair[44]
AntagomirsAMOs with the 2′-O chemical modification and phosphorothioate bonds to increase intracellular stability and with a conjugated cholesterol tail at the 3′-end to favor cell membrane permeationCompetitive inhibition of the target mature miRNA by base pair[45]
Locked nucleic acids (LNA)-based AMOsAMOs containing an additional methylene link between the 2′-O atom and the 4′-C atom, that locks ribose into a more thermodynamically stable conformationHigh-affinity base pair with their target mature miRNA. Inhibition of miRNA activity[46]
Small molecules miRNA inhibitorsSmall molecules (chemical compounds) that interfere with miRNA biogenesis and/or activityInhibition of a specific miRNA biogenesis and/or activity by chemical structure-based docking to miRNA precursor or to mature miRNA[47]
miRNA spongesRNA transcripts presenting multiple tandem repeats of the binding site (seed sequence) of the miRNA to be targetedThey stably interact with the endogenous target miRNA, preventing its interaction with its target mRNAs[48]
miRNA masksSingle-stranded 2′-O′methyl-modified antisense oligonucleotides totally complementary to the miRNA binding sites in the 3′-UTR of the target mRNAThey “mask” the target mRNA from the endogenous miRNA, preventing the miRNA-driven suppression of protein translation[49]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Marini, F.; Brandi, M.L. Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy. Int. J. Mol. Sci. 2021, 22, 7352. https://doi.org/10.3390/ijms22147352

AMA Style

Marini F, Brandi ML. Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy. International Journal of Molecular Sciences. 2021; 22(14):7352. https://doi.org/10.3390/ijms22147352

Chicago/Turabian Style

Marini, Francesca, and Maria Luisa Brandi. 2021. "Role of miR-24 in Multiple Endocrine Neoplasia Type 1: A Potential Target for Molecular Therapy" International Journal of Molecular Sciences 22, no. 14: 7352. https://doi.org/10.3390/ijms22147352

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop